Last reviewed · How we verify
PNEUMOSIL®
PNEUMOSIL is a pneumococcal conjugate vaccine that stimulates immune responses against Streptococcus pneumoniae by presenting polysaccharide antigens conjugated to a protein carrier.
PNEUMOSIL is a pneumococcal conjugate vaccine that stimulates immune responses against Streptococcus pneumoniae by presenting polysaccharide antigens conjugated to a protein carrier. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal pneumonia.
At a glance
| Generic name | PNEUMOSIL® |
|---|---|
| Also known as | Serum Institute of India Pneumococcal conjugate vaccine (SIIPL-PCV ) |
| Sponsor | Vabiotech |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (13 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains capsular polysaccharides from 13 serotypes of S. pneumoniae conjugated to a diphtheria toxoid carrier protein. This conjugation enhances T-cell dependent immune responses, promoting both antibody production and cellular immunity against pneumococcal infection. The vaccine is designed to provide protection against invasive pneumococcal disease and pneumococcal pneumonia across multiple serotypes.
Approved indications
- Prevention of invasive pneumococcal disease in infants and children
- Prevention of pneumococcal pneumonia
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Opportunistic Pneumococcal Immunisation Trial in MALnutrition (PHASE4)
- Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants (PHASE3)
- Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PNEUMOSIL® CI brief — competitive landscape report
- PNEUMOSIL® updates RSS · CI watch RSS
- Vabiotech portfolio CI